Document is current

Any future updates will be listed below

Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study

Crossref DOI link: https://doi.org/10.1038/s41392-025-02498-z

Published Online: 2026-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark